Scott's Walk-Up BBQ BarBQ Barbecue Barbeque Bar-B-Q

Atlanta Magazine BBQ Issue July 2010

Scott's Walk Up Barbecue

Scott Panter

Call your Pick-up BBQ order in to: 770-382-1600

Click for new January 2015 Printable Menu


Hours:
Sunday - Closed
Monday - Closed
Tuesday - 10:30 - 2:30
Wednesday - 10:30 - 2:30
Thursday - 10:30 - 8:00 p.m.
Friday - 10:30 - 8:00 p.m.
Saturday - 10:30 - 8:00 p.m.


Welcome to Scott's Walk-up Bar-B-Q

Why "walk-up?" That's just part of our commitment to simplicity. Walk in the door and walk up to the counter to place your order for good food. We'll bring it to your table or you can order it "to go."

There are three things we want you to know about Scott's Walk-up Bar-B-Q.

It's Simple. Nothing fancy here. We specialize in Bar-B-Q, and since that's all we do, you get the best we've got to offer.

It's traditional. Southern, smoked pork "que" and ribs with just the right side items. It's hometown Bar-B-Q at its best.

It's good.
Just what you want when you're hungry. Even if you're in a hurry, you know we've taken our time to make it just right.

We appreciate your business and hope you enjoy your meal.

Scott's Three Famous Sauces
Scott's Original Georgia Style BBQ Sauce
North Carolina (vinegar) Style BBQ Sauce
Carolina (mustard) Style BBQ Sauce

Our One-and-Only Location:
206 N. Tennessee Street, Cartersville, Ga. 30120
Between Tabernacle Baptist Church and Arco Printing.
On Tennessee St., three blocks north of Main Street.

Scott's Walk-up Bar-B-Q is committed to preparing the best in traditional Southern BBQ in a clean, inviting environment. We want every guest to be satisfied and to leave happy.
- Scott Panter

© 2008 - 2015 Scott's Walk-up Bar-B-Q

Web Page courtesy of Paul Quillen's Emini Futures Day Trading Course

WSJ.com: Heard on the Street

The Tweets and Yelps of an Overvalued Market

Both Twitter and Yelp were priced for hypergrowth that now looks less certain.

China's Thumb on Fed Rate-Rise Scale

The Federal Reserve is trying to balance the outlook for jobs and inflation as it considers a rate increase. China’s market turmoil could weigh on its deliberations.

Gilead: the Apple of the Biotech World

Gilead faces short-term challenges as its hepatitis C franchise slows. But the stock is a rare example of biotech value.

Boardroom Soap Opera at P&G Hasn't Helped Shares

Ahead of the Tape: A.G. Lafley’s return to Procter & Gamble didn’t revive its fortunes as hoped.

Barclays Returns More Mysterious Than Bankable

Barclays was expected to explain how it will hit higher return targets in its latest set of results, but detail is still lacking.

Investors Need to Check Peugeot's Speed

Peugeot has done well in cutting costs and maintaining pricing discipline. But the outlook is getting tougher for the French carmaker.

As China's Stock Market Boils, Yuan Will Stay Cool

A weaker yuan may make economic sense, but Beijing can hardly afford a bout of currency weakness on top of everything else.

Twitter Must Lead, Not Follow, on User Growth

Twitter recognizes it has a growth problem but it will be hard to fix.

Pfizer's Dollar Dilemma Adds Pressure for Deal Making

Pfizer’s strong results were undermined by currency effects—which also raise pressure to do a deal.

Rental Demand Supplies Home-Building Opportunity

A tight market is pushing rents higher, but new supply is on the way.

BP Still Needs to Drill Business for Cash

BP has been active in cutting in response to the lower oil price environment. Its mixed success just reflects the challenge for the oil and gas sector.

Don't Check Out of Marriott

Ahead of the Tape: Like surging Airbnb, Marriott International has an enviable asset-light approach to lodging.

Zurich Insurance Bid for RSA Would Be a Gamble

U.K.-based insurer RSA has big uncertainties around capital, pensions and profitability.

Baidu's Reinvention Leaves Investors Searching for Profits

Baidu is investing heavily in new services to keep pace with rivals, eating up profits in the process.

GlaxoSmithKline Needs More Quiet Victories

The U.K. pharmaceuticals company has had repeated problems in recent years. It needs consistent, if unremarkable, performance from here.

Allergan's Healthy Price May Come With Side Effects

While investors are excited about Allergan’s pursuit of more deals, they have to hope it doesn’t bite off more than it can chew.

China Stock-Market Recovery Goes All Wobbly

The dam Beijing hastily built to hold back the selloff has sprung a major leak.

Twitter Is No Bargain

Ahead of the Tape: Twitter’s recent stumble creates the appearance of a possible bargain compared with rival social network Facebook, but the gulf between them is vast.

Teva's Allergan Deal Looks a Healthier Mouthful

Teva’s $40.5 billion deal to buy Allergan’s generics business looks a lower risk option than its hostile pursuit of Mylan.

copyright © 2015 Dow Jones & Company, Inc.